Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001127602-11-033096)

Filing Details

Accession Number:
0001127602-11-033096
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-22 16:18:53
Reporting Period:
2011-12-21
Filing Date:
2011-12-22
Accepted Time:
2011-12-22 16:18:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1022079 Quest Diagnostics Inc DGX Services-Medical Laboratories (8071) 161387862
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222676 Robert Hagemann C/O Quest Diagnostics Incorporated
3 Giralda Farms
Madison NJ 07940		 Svp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-21 1,650 $35.53 141,325 No 4 M Direct
Common Stock Disposition 2011-12-21 1,650 $57.74 139,675 No 4 S Direct
Common Stock Acquisiton 2011-12-21 2,500 $48.74 142,175 No 4 M Direct
Common Stock Disposition 2011-12-21 2,500 $57.76 139,675 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2011-12-21 1,650 $0.00 1,650 $35.53
Common Stock Stock Options (Right to Buy) Disposition 2011-12-21 2,500 $0.00 2,500 $48.74
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2012-02-27 No 4 M Direct
0 2012-02-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,767 Indirect SDCP
Footnotes
  1. The options vested in three installments on April 17, 2003, February 27, 2004 and February 27, 2005.
  2. The options vested in three annual installments on February 22, 2006, February 22, 2007 and February 22, 2008.
  3. This exercise and sale reported were effected pursuant to Rule 10b-5-1 sales plan adopted by the reporting person on February 7, 2011.
  4. This transaction was executed in multiple trades at prices ranging from $57.50 to $57.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $57.50 to $57.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. This amount also includes exempt purchases made under the Company's stock purchase plan.
  7. These underlying shares were acquired on a periodic basis by the trustee of the Company's Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments), divided by the market price of the Company's stock as of that date.